Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program

J Am Acad Dermatol. 2020 Sep;83(3):955-957. doi: 10.1016/j.jaad.2020.01.059. Epub 2020 Jan 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adverse Drug Reaction Reporting Systems / statistics & numerical data*
  • B7-H1 Antigen / antagonists & inhibitors*
  • B7-H1 Antigen / immunology
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Pharmacovigilance*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Skin Diseases, Vesiculobullous / chemically induced
  • Skin Diseases, Vesiculobullous / epidemiology*
  • Skin Diseases, Vesiculobullous / immunology
  • United States / epidemiology
  • United States Food and Drug Administration / statistics & numerical data

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • Immune Checkpoint Inhibitors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor